SCHEMBL4905983

SCHEMBL4905983

O=C(O)c1cccnc1Nc1cccc(Cl)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 7/20 0.72
MEN1 O00255 6/20 0.72
KMT2A Q03164 6/20 0.72
RAB9A P51151 5/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
LMNA P02545 4/20 0.66
ALDH1A1 P00352 4/20 0.66
HTT P42858 3/20 0.66
PKM P14618 2/20 0.66
MAPK1 P28482 1/20 0.66
GMNN O75496 1/20 0.66
TTR P02766 1/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
NFKB1 P19838 1/20 0.66
UGT1A1 P22309 1/20 0.66
PTGS1 P23219 1/20 0.66
PTGS2 P35354 1/20 0.66
PMP22 Q01453 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9132692 0.89 NPC1 (0.58) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL4686279 0.88 DHODH (0.76) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL5255345 0.87 LMNA (0.71) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL7271426 0.85 MEN1 (0.58) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL6324644 0.84 DHODH (0.72) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL9469395 0.84 DHODH (1.00) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL479877 0.83 DHODH (1.00) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL10144303 0.83 MEN1 (0.71) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL15636690 0.83 LMNA (0.78) DHODHMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL12478330 0.82 DHODH (0.71) DHODHMEN1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116574053-A RIPK1 kinase target inhibitor and medical application thereof 中国药科大学 2023-08-11 CN disclosed
CN-114989079-B RIPK1 kinase target inhibitor and medical application thereof 中国药科大学 2023-06-23 CN disclosed
CN-114989079-A RIPK1 kinase target inhibitor and medical application thereof 中国药科大学 2022-09-02 CN disclosed
US-20080255126-A1 Inhibitors of post-proline cleaving proteases FERRING B.V. 2008-10-16 US disclosed
US-7335677-B2 Inhibitors of dipeptidyl peptidase IV FERRING B.V. (NL) 2008-02-26 US disclosed
EP-1770093-A1 Pyrido¬2,3-d|pyrimidine derivatives as phosphodiesterase inhibitors Roche Palo Alto LLC (US) 2007-04-04 EP disclosed
US-20050043299-A1 Inhibitors of dipeptidyl peptidase iv FERRING B. V. 2005-02-24 US disclosed
EP-1446116-A1 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FERRING B.V. (NL) 2004-08-18 EP disclosed
WO-2003035057-A1 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FERRING B.V. (NL) 2003-05-01 WO disclosed
CN-1040327-C Optionally substituted pyrido [2,3-d] pyrimidine-2,4(1H,3H)-diones and pyrido [2,3-d] pyrimidine-2(1H,3H)-ones SYNTEX INC (US) 1998-10-21 CN disclosed
US-5439916-A Antiallergens,-inflammatory and -ulcer agents; hypotensive agents; immunosuppressants; skin disorders SCHERING CORPORATION (US) 1995-08-08 US disclosed
EP-0631580-A1 PYRIDO 2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-01-04 EP disclosed
WO-1993019068-A1 PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1993-09-30 WO disclosed
US-5126352-A Antiallergy, antiinflammatory, antiulcer, hypotensive, antibody inhibitors SCHERING CORPORATION (US) 1992-06-30 US disclosed
US-5116840-A Antiulcer, antiinflammatory, hypotensive, immunosuppressants SCHERING CORPORATION (US) 1992-05-26 US disclosed
EP-0229823-B1 POLYCYCLIC QUINOLINE, NAPHTHYRIDINE AND PYRAZINOPYRIDINE DERIVATIVES SCHERING CORPORATION (US) 1991-09-25 EP disclosed
US-4988705-A Antiallergens and -inflammatory agents; hypotensive agents immunological suppression; hyperproliferative skin disorders such as psoriasis SCHERING CORPORATION (US) 1991-01-29 US disclosed
US-4810708-A ANTIALLERGY, IMMUNOSUPPRESSIVE SCHERING CORPORATION (US) 1989-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043299-A1 Inhibitors of dipeptidyl peptidase iv DPP4, DPP9, DPP3 DHODH 2270/4885MEN1 3528/4885KMT2A 3490/4885
US-20080255126-A1 Inhibitors of post-proline cleaving proteases PREP, PEPD, DPP4 DHODH 2709/4885MEN1 3322/4885KMT2A 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.